Abstract Abstract Abstract: Haemophilia replacement factors, both plasmaderived and recombinant, are in relatively short supply and are high-cost products. This has stymied the study and development of alternative methods of administration of haemophilia therapy even in the most economically advanced countries, owing to the large amounts of material needed because bioabsorption and bioavailability of haemophilic factors can be less than 10% when using non-intravenous routes of delivery.
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The haemophilias are congenital disorders characterized by frequent bleeding episodes, especially into the joints and muscles, that cause severe arthritis and crippling. Untreated severe haemophilia patients rarely survive past adolescence.
The most common haemophilias are caused by congenital deficiency in the clotting proteins factor (F) VIII (haemophilia A) or FIX (haemophilia B), which occur in about 1 : 5,000 and 1 :
23,000 male children, respectively. These patients are currently treated with replacement therapy using intravenous administration of purified FVIII or FIX produced by purification from donor plasma or in cell-culture bioreactors. According to a 1995 audit in the state of California, the average healthcare cost for haemophilia patients receiving what is now considered suboptimal care was US$ 140,000 per patient per year of life [1] , of which the overwhelming majority represents the direct cost of the clotting factor concentrate. Replacement of clotting Van Cott, Monahan, Nichols, Velander 3 factor after a haemorrhage is recognized as a suboptimal treatment, as some damage still ensues. Optimal therapy consists of regular replacement of the clotting factor to prevent bleeding episodes. Some of the most urgent problems that complicate the clinical situation include:
1. optimal care of patients in the developed countries is not possible because of the high cost and insufficient supply of clotting factors for replacement therapy; 2. there is currently no access to clotting factors for replacement therapy for 80% of the world's haemophiliacs;
3. clotting factor shortages occur and are exacerbated by raw material shortages (i.e. plasma) and productionplant shutdowns;
4. there is a lack of affordable and adequate amounts of clotting factors for alternative routes of administration, such as oral dosage, which would circumvent the complications and difficulties of intravenous therapy.
The high cost of purified haemophilic factor proteins severely limits treatment in the most developed countries to therapy needed when bleeding occurs (episodic treatment) [2] , and regrettably, little to no treatment for 80% of the world's haemophilia A and B patients, who live in developing countries [3] . Episodic therapy, compared with preventative or prophylactic therapy, is suboptimal for severe haemophilia, but still requires on average at least 50,000 international units (IU) of FIX or more per patient per year [4] at an average wholesale price of US$ 1.18 per IU [5] . The limited supply of donor plasma, the low productivity of cell culture bioreactors, and high development costs of about US$ 800,000,000 for a new Haemophilic Factors Produced by Transgenic Livestock 4 therapeutic product [6] contribute to the high cost of haemophilic factor proteins. As a result, the limited supply of either plasma or recombinant factors precludes the broad use of prophylactic therapy, which is now regarded as the most effective treatment to reduce the number of bleeding episodes and prevent joint damage [7, 8] .
This paper discusses innovative bioengineering efforts that would provide effective and affordable supplies of replacement clotting factors and thus make possible methods of administration other than intravenous injection to treat haemophilia.
FIX is used as a detailed example, but it is recognized that current research into production and alternative methods of delivery for FVIII closely parallel that of FIX.
Molecular difficulties and ramifications in the Molecular difficulties and ramifications in the Molecular difficulties and ramifications in the Molecular difficulties and ramifications in the production of haemophilic factors production of haemophilic factors production of haemophilic factors production of haemophilic factors Several fundamental biochemical constraints are encountered in the production of recombinant human FIX that make it a scarce protein therapeutic. These constraints lie not only in the relationship between the complexity of FIX function and its structure, but also in the limited productivity that is inherent to animal cells cultured on a large scale. The biological activity of FIX requires a complex molecular structure that contains posttranslational modifications. for the carboxylase enzyme complex [9] . After the N-terminal glutamates are I-carboxylated, the propeptide is removed. and select for I-carboxylated recombinant FIX [11] . Briefly, highly purified BeneFix® contains a mixture of subpopulations with 10, 11 and 12 I-carboxyglutamates [12] . This is consistent with the reported limitations in the ability of Chinese hamster ovary cells to completely I-carboxylate FIX [10] . Another salient feature of BeneFix® is that, unlike plasma-derived FIX products, it contains essentially no phosphorylation at Ser158, and only 15% sulphation of Tyr155 [12] . Pharmacoki-7 netic studies in humans indicate that this lack of phosphorylation and sulphation may lead to a modestly lower initial recovery of activity in plasma after intravenous infusion for BeneFix®, compared with plasma-derived FIX [13] .
Other post-translational modifications made to FIX include N-hydroxylation of Asp63, two N-linked glycosylation sites at Asn157 and Asn167 within the activation peptide, and four Olinked glycosylation sites at Ser53, Ser61, Thr159, and Thr169
( Fig. 1) . The specific contributions of these post-translational modifications to FIX biological activity have not yet been determined. However, the presence of terminal sialic acid moieties on N-linked oligosaccharides has been shown to significantly improve the circulation half-life of therapeutic proteins [14] . Plasma-derived FIX has complex N-linked oligosaccharides that are tri-and tetra-antennary and terminated with sialic acid (N-acetylneuraminic acid) [15] . N-linked oligosaccharides of BeneFix® are similar to plasma-derived FIX [12] .
The production of FVIII by genetically engineered animal cells is even more highly constrained by molecular complexity than is FIX [16] . For example, FVIII is limited in its rate of secretion, which is related to its post-translational structure.
Post-translational structures arising from proteolytic processing, sulphation, and glycosylation each contribute to FVIII biological function. Some of these rate limitations can be ameliorated by molecular engineering of the primary structure of the FVIII molecule while still maintaining or even improving the function and stability [17] . However, even with these improvements, the rate of synthesis and secretion of FVIII by any animal cell is arguably one of the most difficult tasks that has been encountered in recombinant protein expression. Thus, other improvements in production technology must be made to The resultant low concentration of these haemophilic factors in the bioreactor dictates that downstream processing must both concentrate and purify the final product at very high cost [18] . Typically, the overall production costs will be on the status of large-scale processes needed to consistently produce material that will meet federal regulatory requirements [6, 19] .
The limitations in current manufacturing capacity have a serious impact on haemophilia therapy. For example, even though about 90% of patients in the USA receive recombinant FIX therapy, only 13% of the children with haemophilia B in the USA receive prophylaxis [20] .
The projected process volumes needed to satisfy the estimated clinical demand for prophylactic intravenous therapy for FIX in the USA translate to large capital investment costs in new manufacturing facilities [19] . Fig  Fig Fig  Figure 2 the total milk yield from the average sow is 100-300 L year -1 [21] . Even more important than the consideration of milk volume, however, is the fact that the mammary epithelial cells of the pig are unique among livestock in making the complex post-translational modifications needed for FIX [22] and FVIII [23] biological activity. From a broad biochemical and physiological perspective, the pig is more closely related to humans than the ruminants, which include the cow, sheep, and goat. As an example of the differences between ruminant and pig biochemistry, recombinant FIX production in sheep was unsuccessful, with only low levels of biologically active FIX being produced: less than 0.5 ng of biologically active FIX could be recovered from each millilitre of milk [24] . The sheep was even less productive than donor plasma at 0.0001 U mL -1 of milk. In contrast, recombinant human FIX has been produced at levels up to 100 U mL -1 of milk in transgenic pigs [22] , and proper proteolytic cleavage of recombinant FVIII to a mature two-chain form has been demonstrated in the milk [23] . With respect to N-linked glycans that are needed for long circulation half-life in therapeutic proteins [14] , endogenous porcine milk glycoproteins such as lactoferrin contain complex glycans terminated with N-acetylneuraminic acid (sialic acid) [25] . In contrast, ruminant lactoferrins contain undesirable high-mannose glycans [25] , and recombinant antithrombin III produced in transgenic goats also contained high-mannose glycans [26] .
Thus, ruminants are probably unable to make a recombinant The regulatory concerns for production of haemophilic factors derived from transgenic animals have been largely delineated.
In recognition of the feasibility of this production method, the intramuscular, and intraperitoneal [32, 33] . While all of these routes resulted in measurable FIX activity, the subcutaneous and intramuscular injections resulted in bioavailabilities of 63.5% and 82.8%, respectively, in the haemophilia B dog model [32] . Subcutaneous administration of high concentrations of up to 4,000 IU mL -1 resulted in bioavailabilities of 35% in cynomolgus monkeys and 46% in haemophilia B dogs [33] . Importantly, while all of these extravascular delivery routes are less efficient than intravenous, they provide a combination of simplicity of administration and sustained FIX activity. These advantages may be greatest when applied to factor prophylaxis in children, for whom intravenous access is most troublesome, [35] also used a liposomal formulation, administered a dose of 14 U of plasma-derived FIX kg -1 bodyweight in a 9.2-kg dog, and measured 125% of normal FIX activity by activated partial throboplastin time. In both these FVIII and FIX oral-dosage studies, however, sufficient numbers of animal or human subjects were not investigated to assess the variability in bioavailability that would be expected using oral dosage. It is likely that at that time, the supply of plasma-derived materials precluded the effective parametric study of appropriate formulations to determine optimum bioavailability.
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The They state in their Recommendations [36] that manufacturers should strive to make coagulation products less expensive and that methods such as the use of transgenic animals would increase supply and availability. It is also clear that alternative delivery methods that dramatically improve the ease of treatment and quality of patient life, particularly for children, will be feasible if an abundance of haemophilic factors becomes available. This may apply even more strongly to locations where patient care and compliance are more challenging due to economic conditions.
